Metabolic disorders in patients with chronic kidney failure

Physiological Research

Volumn 56, Issue 6, 2007, Pages 697-705

  Cibulka, R ^a   Racek, J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cardiovascular disease; Chronic kidney failure; Dialysis; Metabolic disorders

Indexed keywords

PROTEIN;

ACID BASE BALANCE; ANEMIA; ANIMAL; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; HUMAN; HYPERHOMOCYSTEINEMIA; LIPID METABOLISM; METABOLIC DISORDER; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; RENAL OSTEODYSTROPHY; RENAL REPLACEMENT THERAPY; REVIEW;

ACID-BASE EQUILIBRIUM; ANEMIA; ANIMALS; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASES; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; LIPID METABOLISM; METABOLIC DISEASES; OXIDATIVE STRESS; PROTEINS; RENAL DIALYSIS; RENAL OSTEODYSTROPHY;

EID: 41749101584     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (58)

1. ALVESTRAND A: Carbohydrate and insulin metabolism in renal failure. Kidney Int Suppl 62: S48-S52, 1997.
2. ATTMAN PO, SAMUELSSON O, ALAUPOVIC P: Lipoprotein metabolism and renal failure. Am J Kidney Dis 21: 573-592, 1993.
3. CIBULKA R, RACEK J, VESELA E: The importance of L-carnitine in patients with chronic renal failure treated with hemodialysis (in Czech). Vnitr Lek 51: 1108-1113, 2005.
4. DAYAL S, LENTZ SR: ADMA and hyperhomocysteinemia. Vasc Med 10 (Suppl 1): S27-S33, 2005.
5. DE DEYN PP, VANHOLDER R, D'HOOGE R: Nitric oxide in uremia: Effects of several potentially toxic guanidino compounds. Kidney Int 63 (Suppl 84): S25-S28, 2003.
6. DIAZ-BUXO JA, WOODS HF: Protecting the endothelium: A new focus for management of chronic kidney disease. Hemodial Int 10: 42-48, 2006.
7. DIRICAN M, AKCA R, SARANDOL E, DILEK K: Serum paraoxonase activity in uremic predialysis and hemodialysis patients. J Nephrol 17: 813-818, 2004.
8. DUPLAIN H, BURCELIN R, SARTORI C, COOK S, EGLI M, LEPORI M, VOLLENWEIDER P, PEDRAZZINI T, NICOD P, THORENS B, SCHERRER U: Insulin resistance, hyperlipidemia and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 104: 342-345, 2001.
9. DURAK I, AKYOL O, BASESME E, CANBOLAT O, KAVUTCU M: Reduced erythrocyte defense mechanisms against free radical toxicity in patients with chronic renal failure. Nephron 66: 76-80, 1994.
10. EISELT J, RACEK J, OPATRNÝ K Jr: Free radicals and extracorporeal renal replacement therapy (in Czech). Vnitr Lek 45: 319-324, 1999.
11. EISELT J, RACEK J, OPATRNÝ K Jr, TREFIL L, STEHLÍK P: The effect of intravenous iron on oxidative stress in hemodialysis patients at various levels of vitamin C. Blood Purif 24: 531-537, 2006.
12. EISELT J, RACEK J, OPATRNÝ K Jr: Free radicals and extracorporeal renal replacement therapy. Vnitr Lek 45: 319-324, 1999.
13. ESCHBACH JW, ADAMSON JW: Anemia of end-stage renal disease. Kidney Int 28: 1-5, 1985.
14. FERRANNINI E, BUZZIGOLI G, BONADONNA R, GIORICO MA, OLEGGINI M, GRAZIADEI L, PEDRINELLI R, BRANDI L, BEVILACQUA S: Insulin resistance in essential hypertension. N Engl J Med 317: 350-357, 1987.
15. FOLEY RN, PARFREY PS, SARNAK MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 (Suppl 3): S112-S119, 1998.
16. GIACHELLI CM, SPEER MY, LI X, RAJACHAR RM, YANG H: Regulation of vascular calcification: roles of phosphate and osteopontin. Circ Res 96: 717-722, 2005.
17. GO AS, CHERTOW GM, FAN D, MCCULLOCH CE, HSU CY: Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004.
18. GOLPER TA, GORAL S, BECKER BN, LANGMAN CB: L-carnitine treatment of anemia. Am J Kidney Dis 41 (Suppl 4): S27-S34, 2003.
19. GONZALEZ EA, MARTIN KJ: Renal osteodystrophy. Rev Endocr Metab Disord 2: 187-193, 2001.
20. GUARNIERI G, FONDA M, SITULIN R, VASILE A, TOIGO G, CATTIN L: Effects of L-carnitine supplementation in the dialysate on serum lipoprotein composition of hemodialysis patients. Contrib Nephrol 98: 36-43, 1992.
21. IKIZLER TA: Protein and energy: recommended intake and nutrient supplementation in chronic dialysis patients. Semin Dial 17: 471-478, 2004.
22. IKIZLER TA, WINDGARD RL, HARVELL J, SHYR Y, HAKIM RM: Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Kidney Int 55: 1945-1951, 1999.
23. KALANTAR-ZADEH K, IKIZLER TA, BLOCK G, AVRAM MM, KOPPLE JD: Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 42: 864-881, 2003.
24. KALANTAR-ZADEH K, STENVINKEL P, BROSS R, KHAWAR OS, RAMMOHAN M, COLMAN S, BENNER D: Kidney insufficiency and nutrient-based modulation of inflammation. Curr Opin Clin Nutr Metab Care 8: 388-396, 2005.
25. KLAUNIG JE, XU Y, ISENBERG JS, BACHOWSKI S, KOLAJA KL, JIANG J, STEVENSON DE, WALBORG EF Jr: The role of oxidative stress in chemical carcinogenesis. Environ Health Perspect 106 (Suppl 1): 289-295, 1998.
26. KONE BC: Nitric oxide in renal health and disease. Am J Kidney Dis 30: 311-333, 1997.
27. KOPPLE JD: Effect of nutrition on morbidity and mortality in maintenance dialysis patients. Am J Kidney Dis 24: 1002-1009, 1994.
28. KOVACIC V, ROGULJIC L, KOVACIC V: Metabolic acidosis of chronically hemodialyzed patients. Am J Nephrol 23: 158-164, 2003.
29. KRAUT JA, KURTZ I: Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment. Am J Kidney Dis 45: 978-993, 2005.
30. KRONENBERG F, NEYER U, LHOTTA K, TRENKWALDER E, AUINGER M, PRIBASNIG A, MEISL T, KONIG P, DIEPLINGER H: The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol 10: 1027-1036, 1999.
31. LEVEY AS, EKNOYAN G: Cardiovascular disease in chronic renal disease. Nephrol Dial Transplant 14: 828-833, 1999.
32. LEVEY AS, ECKARDT KU, TSUKAMOTO Y, LEVIN A, CORESH J, ROSSERT J, ZEEUW D, HOSTETTER TH, LAMEIRE N, EKNOYAN G: Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67: 2089-2100, 2005.
33. LIM PS, WEI YH, YU YL, KHO B: Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 14: 2680-2687, 1999.
34. LINDNER A, CHARRA B, SHERRARD DJ, SCRIBNER BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290: 697-701, 1974.
35. LIU Y, CORESH J, EUSTACE JA, LONGENECKER JC, JAAR B, FINK NE, TRACY RP, POWE NR, KLAG MJ: Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 291: 451-459, 2004.
36. LUND RJ, DAVIES MR, SURESH M, HRUSKA KA: New discoveries in the pathogenesis of renal osteodystrophy. J Bone Miner Metab 24: 169-171, 2006.
37. MACKNESS MI, ARROL S, ABBOTT CA, DURRINGTON PN: Protection of low-density lipoprotein against oxidative modification by high density lipoprotein associated paraoxonase. Atherosclerosis 104: 129-135, 1993.
38. MEHROTRA R, KOPPLE JD, WOLFSON M: Metabolic acidosis in maintenance dialysis patients: clinical considerations. Kidney Int 64 (Suppl 88): S13-S25, 2003.
39. MIYATA T, INAGI R, KUROKAWA K: Diagnosis, pathogenesis, and treatment of dialysis-related amyloidosis. Miner Electrolyte Metab 25: 114-117, 1999.
40. NATIONAL KIDNEY FOUNDATION: K/DOQI, clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 39 (2 Suppl 1): S1-S266, 2002. http://www.kidney.org/ professionals/kdoqi/guidelines_ckd/toc.htm.
41. NATIONAL KIDNEY FOUNDATION: K/DOQI, clinical practice guidelines for bone metabolism and disease in chronic kidney disease, guideline 7. 2004. http://www.kidney.org/professionals/kdoqi/ guidelines_bone/Guide7.htm.
42. NATIONAL KIDNEY FOUNDATION: K/DOQI, clinical practice guidelines for managing dyslipidemias in chronic kidney disease, part 3, guideline 4. 2006. http://www.kidney.org/professionals/kdoqi/guidelines_lipids/iii.htm.
43. NEDELJKOVIC ZS, GAKCE N, LOSCALZO J: Mechanisms of oxidative stress and vascular dysfunction. Postrad Med J 79: 195-199, 2003.
44. OH MS, URIBARRI J, WEINSTEIN J, SCHREIBER M, KAMEL KS, KRAUT JA, MADIAS NE, LASKI ME: What unique acid-base considerations exist in dialysis patients? Semin Dial 17: 351-364, 2004.
45. PERNA AF, INGROSSO D, SATTA E, LOMBARDI C, ACANFORA F, DE SANTO NG: Homocysteine metabolism in renal failure. Curr Opin Clin Nutr Metab Care 7: 53-57, 2004.
46. PERNA AF, CAPASSO R, LOMBARDI C, ACANFORA F, SATTA E, INGROSSO D: Hyperhomocysteinemia and macromolecule modifications in uremic patients. Clin Chem Lab Med 43: 1032-1038, 2005.
47. RACEK J, RUSŇÁKOVÁ H, TREFIL L, SIALA KK: The influence of folate and antioxidants on homocysteine levels and oxidative stress in patients with hyperlipidemia and hyperhomocysteinemia. Physiol Res 54: 87-95, 2005.
48. RASIC-MILUTINOVIC Z, PERUNICIC-PECKOVIC G, PLJESA S: Clinical significance and pathogenic mechanism of insulin resistance in chronic renal insufficiency (part II): pathogenic factors of insulin resistance in chronic renal insufficiency. Med Pregl 53: 159-163, 2000.
49. RAVANI P, TRIPEPI G, MALBERTI F, TESTA S, MALLAMACI F, ZOCCALI C: Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 16: 2254-2256, 2005.
50. RIGALLEAU V, GIN H: Carbohydrate metabolism in uremia. Curr Opin Clin Nutr Metab Care 8: 463-869, 2005.
51. SANTORO A: Anemia in renal insufficiency. Rev Clin Exp Hematol Suppl 1: 12-20, 2002.
52. SHINOHARA K, SHOJI T, EMOTO M, TAHARA H, KOYAMA H, ISHIMURA E, MIKI T, TABATA T, NISHIZAWA Y: Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 13: 1894-1900, 2002.
53. SHOJI T, EMOTO M, SHINOHARA K, KAKIYA R, TSUJIMOTO Y, KISHIMOTO H, ISHIMURA E, TABATA T, NISHIZAWA Y: Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 12: 2117-2124, 2001.
54. SILVER J: Molecular mechanisms of secondary hyperparathyroidism. Nephrol Dial Transplant 15: 2-7, 2000.
55. SNYDER S, PENDERGRAPH B: Detection and evaluation of chronic kidney disease. Am Fam Physician 72: 1723-1732, 2005.
56. SULIMAN ME, LINDHOLM B, BARANY P, BERGSTROM J: Hyperhomocysteinemia in chronic renal failure patients: relation to nutritional status and cardiovascular disease. Clin Chem Lab Med 39: 734-738, 2001.
57. TAKAMITSU Y, NAKANISHI T: Association of endothelial dysfunction with sulfur amino acid metabolism in chronic renal failure. Am J Kidney Dis 38 (Suppl 1): S95-S99, 2001.
58. WANNER C, KRANE V: Uremia-specific alterations in lipid metabolism. Blood Purif 20 (Suppl 1): 451-453, 2002.